Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carnitine Supplementation in Type 2 Diabetes
NCT03230812Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Mar 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of acetyl-l-carnitine in type 2 diabetes mellitus (T2DM), sponsored by Maastricht University Medical Center+. Primary endpoints: Insulin sensitivity at 96 days and Metabolic flexibility at 96 days. Started Mar 2018; status: completed.
02
Drugs
acetyl-l-carnitine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03230812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230812.